InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.16
(
0.47%
)
US TECH 100
18,024.00
(
0.56%
)
Dow Jones
39,497.54
(
0.13%
)
Brent Oil
79.49
(
0.00%
)
Bitcoin
60,659.27
(
-0.36%
)
Post# of 252819
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120250
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: poorgradstudent post# 101549

Friday, 09/03/2010 12:55:42 PM

Friday, September 03, 2010 12:55:42 PM

Post# of 252819
Identity of Revlimid-patent challenger revealed to be Natco:

http://www.reuters.com/article/idCNN0326933120100903

#msg-53738423 is a good background read on how CELG intends to maintain Revlimid exclusivity.

p.s. Natco is the Indian company that thinks it can make a generic Copaxone for the US market (#msg-29902618, #msg-52598947).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up